Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 7/20 | 0.40 |
| ▸ | JAK3 | P52333 | 6/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.38 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | FGR | P09769 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | SIK1 | P57059 | 1/20 | 0.36 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123723 | 1.00 | KCNH2 (0.42) | KCNH2JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL3133512 | 0.91 | NUAK1 (0.47) | KCNH2JAK2JAK3NTRK1NUAK1 | |
| SCHEMBL3129678 | 0.91 | NUAK1 (0.47) | KCNH2JAK2JAK3NTRK1NUAK1 | |
| SCHEMBL3021633 | 0.88 | KCNH2 (0.52) | KCNH2JAK2JAK3NTRK1ABL1 | |
| SCHEMBL3029292 | 0.87 | NTRK1 (0.44) | KCNH2JAK2JAK3NTRK1ABL1 | |
| SCHEMBL3136094 | 0.87 | NTRK1 (0.45) | KCNH2JAK2NTRK1ABL1FGR | |
| SCHEMBL3136074 | 0.87 | NTRK1 (0.45) | KCNH2JAK2NTRK1ABL1FGR | |
| SCHEMBL3133128 | 0.87 | JAK3 (0.53) | KCNH2JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL3139531 | 0.87 | JAK3 (0.53) | KCNH2JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL3263756 | 0.85 | NTRK1 (0.41) | KCNH2JAK2JAK3NTRK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853602-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-07-14 | — | — | EP | claimed |
| US-7622482-B2 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA (SE) | 2009-11-24 | — | — | US | claimed |
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | claimed |
| EP-1853602-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ERBB4, ERBB2, ABL1 | KCNH2 2439/4885JAK2 61/4885JAK3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.